Navigation Links
Rudd Report Gives AMDL, Inc. a Strong Buy Recommendation in Year-End Financial Research Report
Date:1/6/2009

TUSTIN, Calif., Jan. 6 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), a vertically integrated pharmaceutical company with operations in China and the US, announced today industry analyst Lauren Rudd has issued a strong buy recommendation for AMDL in his year-end financial research report on the Company.

The report projects a 12-month target price of $5.00 for AMDL and highlights the Company's:

    -- Consistent, positive historical financial performance over the past
       four years
    -- Most recent operational changes and business updates, including an
       updated overview of AMDL's China-based subsidiary Jade Pharmaceuticals,
       Inc.
    -- FY2009 product pipeline
    -- FY2009 plans for the AMDL ELISA DR-70(R) (FDP) cancer monitoring test;
       best-selling Human Placenta Extract (HPE) anti-aging product line; and
       MYHPV Chip(R) diagnostic test kit which detects approximately 28
       different strains of the Human Papilloma Virus.

The research report also provides a thorough peer group comparison with valuation analyses, views and opinions on AMDL's projected financial performance for the 2009 fiscal year, and historical financials.

According to Mr. Rudd, "AMDL has taken major initiatives to build its strengths while reorganizing top management and still producing respectable financials which has resulted in AMDL being one of the most under priced stocks we have seen in a long time."

A full copy of the report is available for downloading online at http://www.ruddreport.com or by contacting Ms. Kristine Szarkowitz, AMDL's Director Investor Relations, at kszarkowitz@amdl.com.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 490 people in the U.S. and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

     AMDL Contact:
     Kristine Szarkowitz
     Director-Investor Relations
     kszarkowitz@amdl.com
     (Tel :) 206.310.5323

'/>"/>
SOURCE AMDL, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Consumer Reports: Big Promises of Some Infomercial Exercise Machines Fall Flat; Plus, Set Up a Home Gym for Under $100
2. Cardium Reports on Exchange Listing With NYSE Alternext US
3. CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte Closes
4. Joint Commission Reports Positive Survey Results for CHA
5. Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability
6. Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability
7. Risks and Benefits of Egg Donation Reported
8. LegalView Updates its Baxter Heparin Information Portal with Conflicting News Reports on the Possible Dangers
9. Despite Sagging Economy, Viamedic Reports Solid Online Sales for Erectile Dysfunction Drugs
10. 5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes
11. Published reports inaccurate concerning alcohol consumption during pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
(Date:2/5/2016)... New York (PRWEB) , ... February 05, 2016 , ... ... use and find themselves having to wait longer to access the treadmills. It’s a ... New Year’s resolutions to lose weight and get in shape by joining gyms, starting ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... At its ... of Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds ... of the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... Move from on one drop zone to the next using Colorize's dynamic moving camera. ... any project. This package includes a 3D slideshow environment with 1 to 5 focus ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June ... Diseases, a continuing medical education (CME) event presented by the Association for Comprehensive ... a first for ACCORD, whose mission is to provide education, tools, and resources ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ("Aralez") ... POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following ... shareholders of Tribute. The combined company will operate under ... with operations in Canada , ... States . Under the terms of the Agreement ...
(Date:2/5/2016)... 5, 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ... CEO, will be presenting at Source Capital Group,s 2016 Disruptive ... at 2:15 p.m. ET on Wednesday, February 10, ... discussion taking place at 3:15 p.m. ET. http://www.aethlonmedical.com ... hour after the conclusion of the live event. The panel ...
(Date:2/5/2016)... New York , February 5, 2016 ... new Transparency Market Research report states that the global ... in 2014 and is predicted to reach US$185.9 bn ... CAGR of 6.50% from 2014 to 2020. The title ... (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic ...
Breaking Medicine Technology: